BARCELONA, Spain – French antibody developer Gamamabs SA is waiting on safety data for its first-in-class antibody targeting the type II anti-Müllerian hormone receptor (AMHR2) before including dose-expansion cohorts across three gynecological cancer indications.
BARCELONA, Spain – What may well be Europe's least known cell therapy company has just begun a phase III trial of its lead program in a notoriously challenging indication. Rexgenero Ltd. began recruiting diabetic patients with critical limb ischemia (CLI) last week, CEO Joe Dupere told BioWorld Today. He expects the first patient to receive treatment by the end of this month.
BARCELONA, Spain – Biotechnology is more globalized than ever but is also, in certain respects, hyper-localized. That was the contradictory but, at the same time, defensible conclusion one could draw from a panel discussion titled "Stirring the Entrepreneurial Pot in Europe" here at the BIO-Europe Spring meeting.
BARCELONA, Spain – Even if the myriad uncertainties that have accompanied the arrival of the Trump administration in the U.S. mean that business as usual may no longer be possible for many biopharma firms, they still have business to conduct. And that was foremost in the mind of delegates arriving at Barcelona’s International Convention Center (CCIB) Monday.
DUBLIN – The EMA’s big drive for transparency has received pushback from the Court of Justice of the European Union, which has dismissed two appeals the EMA brought against earlier court decisions that barred it from releasing trial data on two drug dossiers.
DUBLIN – Breath Therapeutics Holding BV raised €43.5 million (US$46 million) in a series A round – Europe's largest so far this year – to undertake phase III trials of a drug-device combo, comprising a nebulizer-delivered, liposome-based formulation of cyclosporine A, in lung transplant patients with bronchiolitis obliterans syndrome (BOS), a chronic progressive airway inflammation that has a major impact on survival rates.
DUBLIN – Ingeneron Inc. has secured $20 million in equity investment from its clinical collaborator Sanford Health, enabling it to conduct U.S. clinical trials of its point-of-care cell therapy treatment in several indications.
DUBLIN – Sanofi SA is paying €120 million (US$127 million) up front and could pay up to €495 million more in development and commercial milestones for a 50 percent share in the economics of Astrazeneca plc's MEDI8897, a next-generation successor to its longstanding Synagis (palivizumab) franchise for preventing respiratory syncytial virus (RSV) infection in at-risk infants.
